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The production of concentrated urine inevitably leads to the
precipitation of poorly soluble waste salts in the renal tubular
fluid. These crystallization processes are physiologic and
without consequences as long as all crystals are excreted
with the urine. The retention of crystals in the renal tubules,
however, may lead to tubular nephrocalcinosis. Here, we
present a brief survey of the possible mechanisms involved in
this process, which seems to depend predominantly on the
presence of regenerating/(re)differentiating cells in the renal
tubules. Crystal binding to the surface of these cells can be
mediated by a number of luminal membrane molecules,
including acidic fragment of nucleolin-related protein,
annexin-II, osteopontin, and hyaluronan.
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The definition of the term nephrocalcinosis is not clear. It
often refers to a diffuse renal parenchymal calcification
demonstrable by imaging techniques (e.g., ultrasonography,
computed tomography, X-ray). However, imaging, with its
known limitations, is not able to show the exact location
of the deposits in the kidney. From histological observations
throughout literature, calcifications of the renal tissue can
be found either in the tubules or in the interstitium. To
prevent confusion in this review, the tubular calcifications
will be called tubular nephrocalcinosis, whereas the inter-
stitial calcifications will be called interstitial nephrocalcinosis.
Interstitial nephrocalcinosis has been proposed to start in
the interstitium (beneath the basement membrane) around
the thin limbs of Henle and is thought to give rise to sub-
epithelial calcifications, which are better known as Randall’s
plaques.1 In comparison with nephrocalcinosis, kidney
stones (nephrolithiasis) are found further on in the urological
tract, that is the renal calyces and pelvis. Although
nephrocalcinosis is not necessarily accompanied by nephro-
lithiasis, both intratubular2 and interstitial nephrocalcinosis1
have been proposed to play a role in the development of
specific varieties of kidney stones (Figure 1). Nephrolithiasis
is a major health problem in the western world where it
affects 12% of men and 6% of women at some point in
their lives. Kidney stones are responsible for about 10%
of urological hospital admissions per year and account
for a significant number of visits to the hospital emer-
gency departments.3 Although nephrolithiasis is associated
with much pain and suffering, kidney stones seldom lead to
loss of kidney function. Although less painful, intratubular
nephrocalcinosis may constitute a much greater health risk.
The incidence of tubular nephrocalcinosis is often under-
estimated because of the low sensitivity of radiological
imaging techniques and because most crystals are lost from
the renal tubules during tissue processing for routine
histology.4 Apart from the possibility that tubular nephro-
calcinosis may lead to nephrolithiasis, tubular nephrocalci-
nosis can lead to an (obstruction-induced) tubulopathy.
Massive tubular nephrocalcinosis often leads to end-stage
renal failure in primary hyperoxaluria5 and recently there is
accumulating evidence suggesting that tubular nephrocalci-
nosis also plays an important role in chronic allograft
nephropathy.6–9
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CONCEPTS IN CRYSTAL RETENTION
Ultrafiltrate does not contain calcium oxalate (CaOx) crystals
because of the low levels of supersaturation. The concentra-
tion of oxalate and to a lesser extent that of calcium gradually
increases as a result of oxalate secretion and water
reabsorption, but in physiological conditions CaOx satura-
tion probably does not become high enough to form crystals
in the proximal tubule. The upper limits of metastability
most probably are reached somewhere beyond the thin limbs
of Henle. Late segments of the nephron (e.g., distal tubule,
collecting ducts) and the renal calyces are therefore major
regions of interest for studying crystal retention, respectively,
in tubular nephrocalcinosis and nephrolithiasis. The me-
chanisms involved in the retention of crystals in the renal
calyces are relatively unexplored. At least a subset of stones
seem to grow on Randall’s plaques.10 The mechanisms by
which crystals become associated with these calcium
phosphate-rich structures at the surface of the renal pelvic
wall are unknown. The general perception is that crystals are
not easily retained in the urinary tract. Crystal binding to the
epithelium of the renal tubules may require specific
alterations in the composition of the cell surface, but under
certain conditions it is also possible that relatively large
aggregated clumps of crystals are trapped in the renal
tubules.11 Because the far majority of crystal–cell interaction
studies have been performed with CaOx and renal tubular
cells, this review is focused on mechanisms involved in CaOx
crystal binding to the renal tubular epithelium.
GLYCOCONJUGATES WITH AFFINITY FOR CRYSTALS
During their transit through the nephron, crystals encounter
soluble and membrane-associated glycoconjugates with
affinity for crystals. Whereas only relatively small molecules
or fragments of larger molecules can enter the nephron at
the glomerulus, most tubular fluid glycoproteins, glyco-
lipids, and glycosaminoglycans are synthesized by renal
tubular cells. Through the interaction of cationic calcium
ions with negatively charged glycoconjugates the equili-
brium [Ca2þ ][C2O4
2] product is much higher in urine
than in water. These natural inhibitors of crystallization are
responsible for the delay in stone-salt precipitation in a
supersaturated environment. Although these glycoconjugate
inhibitors play an important role in renal stone disease
and compelling review articles have been devoted to this
subject,12 crystallization inhibition is beyond the scope of this
review.
CaOx CRYSTAL–CELL INTERACTION
In primary hyperoxaluria type I patients with end-stage renal
failure, the rise in serum oxalate ultimately leads to oxalate
crystal deposits in bone, skin, vessels, eyes, and joints
(systemic oxalosis).13 The contact with CaOx crystals of
many eukaryotic cells, including endothelial cells,14 fibro-
blasts,15 leukocytes,16 erythrocytes,16 lung cells,17 and renal
proximal tubular cells18,19 leads to inflammation-mediated
membranolysis and acute necrotic cell death. Cell culture
studies suggest that the response of renal tubular cells to
CaOx crystals is nephron segment-specific. Proximal tubular
cells, which in normal physiological conditions do not
encounter crystals, avidly bind crystals to the brush border
after which the crystals penetrate the plasma membrane
and enter the cell leading to inflammation-mediated
cell death.18–20 However, the handling of CaOx crystals by
renal distal or collecting tubular cells is quite different.
Crystals bind to regenerating/(re)differentiating cells in
subconfluent cultures or in healing scrape wounds, but not
to differentiated cells organized in functional confluent
monolayers.21–23 Even when crystals bind to regenerating/
(re)differentiating Madin–Darby canine kidney (MDCK)-I
cells in a wound, they are not taken up and do not induce
inflammation.24,25 Taken into account that these results are
predominantly obtained from cell culture studies using a
limited number of cell lines assumed to be representative
for the nephron segments involved, they collectively suggest
that CaOx crystals are relatively inert to cells in areas where
their presence is common (e.g., renal collecting ducts, lower
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Figure 1 | Schematic overview of different urological tract
calcifications in the kidney and how they are related to each
other and to the issue of this review. Tubular nephrocalcinosis:
Various conditions and disorders are associated with this form of
renal calcification. In the clinical conditions investigated, crystals were
retained by regenerating/(re)differentiating renal tubular cells,
suggesting a general mechanism in the etiology of tubular
nephrocalcinosis. Although repeatedly proposed, there is no
evidence to date that tubular nephrocalcinosis plays a role in the
growth of stones in the renal calyces. Nevertheless, this form of renal
calcification may lead to reduced renal function because of
obstructive tubulopathy. Interstitial nephrocalcinosis: This form of
renal calcification begins at the basement membrane of the thin
limbs of Henle where calcium phosphate precipitates for unknown
reasons. In some people, these precipitates gradually accumulate in
time to form a Randall’s plaque after eroding through the pelvic wall.
Recently, evidence has been provided that at least a subset of kidney
stones grows on these plaques.
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urinary tract), whereas they cause acute inflammation-
mediated cell death in areas where they are found only
under extreme or pathological circumstances (e.g., blood,
renal proximal tubule) (Table 1).
PROPOSED CRYSTAL-BINDING MOLECULES
Phosphatidylserine
Phosphatidylserine (PS) is the only anionic amino acid-
containing glycerophospholipid in animal cells. It may
comprise up to 20% of the total phospholipid in the plasma
membrane where it is located entirely on the inner monolayer
surface of the plasma membrane. PS plays a role in the
regulation of physiological cell death (apoptosis). The normal
distribution of PS on the inner leaflet of the membrane
bilayer is disrupted during apoptosis because of stimulation
of the enzyme scramblase. Enrichment of the cell membrane
with PS or apoptotic cell death leads to increased levels of
CaOx crystal binding. Crystal binding was also higher after
PS was translocated to the outer leaflet of the lipid bilayer
under the influence of a calcium ionophore. This increase in
crystal binding could be blocked by PS-specific annexin-V.
These results suggested that apoptosis is one of the mecha-
nisms by which CaOx crystals bind to the renal tubular
epithelium.26 This was one of the first attempts to identify
molecules possibly involved in renal crystal retention. To
date, no evidence has been presented that stone formers
express more apoptotic cells in the kidney than non-stone
formers.
N-acetyl neuraminic acid (or sialic acid)
N-acetyl neuraminic acid is the terminal sugar residue of
oligosaccharide side-chains of cell surface glycoconjugates
that provides the cell surface with most of its electronegative
charge. As calcium crystals can be viewed as large cationic
macromolecules, N-acetyl neuraminic acid is a potential
crystal-binding molecule. CaOx crystals avidly bound to
BSC-1 cells (African green monkey cells) and this binding
was significantly lower after digesting N-acetyl neuraminic
acid from the cell surface with neuraminidase (sialidase),
suggesting that crystal binding depends on sialic acid residues
of membrane glycoproteins and glycolipids.27 Later, it was
found that collecting duct MDCK-I cells without affinity
for CaOx crystals contained more sialic acid residues than
cells with affinity for crystals, thereby questioning the role
for sialic acid as crystal-binding molecule.28
Collagen IV
Basement membranes play fundamental roles in differentia-
tion, proliferation, survival, and migration of cells during
embryonic development and wound healing. Members of the
collagen IV family are present in all basement membranes
and are characterized by their ability to form complex,
covalently linked structural scaffolds required for basement
membrane assembly. Rat renal collecting tubular cells and
CaOx crystals formed collagen IV-positive clumps. It was
proposed that collagen IV serves as binding molecule for
crystals after denudation of the renal tubular basement
membrane.29
Acidic fragment of nucleolin-related protein
Nucleolin is a major nucleolar protein of exponentially
growing cells and shuttles between cytoplasma and nucleus.30
Rat inner medullary collecting duct (IMCD) cells were
biotinylated after which all cell surface biotinylated proteins
were lysed and purified using calcium phosphate and CaOx
affinity chromatograhy. One of the most prominent bands
was a 110-kDa calcium-binding glycoprotein. Amino-acid
sequencing and DNA cloning demonstrated a close resem-
blance to nucleolin, which is why it was designated nucleolin-
related protein (NRP).31 Next, they showed that NRP is
randomly expressed over the plasma membrane of prolifer-
ating IMCD cells, reaching peak levels in late stages of mitosis
to decline gradually to undetectable levels with epithelial
maturation. Compared with intact monolayers, regenerating
cells in scrape wounds express higher levels of NRP and bind
more crystals. The acidic fragment (AF) of NRP was
proposed as the active binding region for CaOx crystals.
Apical membrane staining of the AF was higher in cells trans-
fected with the AF of NRP and these cells bound more
crystals than cells transfected with an empty vector. Condi-
tioned medium of human embryonic kidney cells infected
with viruses expressing the AF of NRP inhibited CaOx
binding to IMCD cells, in contrast to conditioned medium
produced by human embryonic kidney cells infected with
wild-type viruses. Crystal binding could be mediated by the
AF of NRP at the plasma membrane and inhibited by the
secreted AF of NRP.21
Annexin-II
Annexin-II (Ax-II) is a calcium- and phospholipid-binding
protein and substrate for protein tyrosine kinases. Ax-II is
actively involved in DNA synthesis and cell proliferation,
which may explain its role in wound healing. The same
Table 1 | Cellular response to calcium oxalate crystals
Tissue Inflammation Condition
Erythrocytes63 + Oxalosisa
Leukocytes16 +
Endothelium14 +
Lung64 +
Joint65 +
Renal proximal tubule19 + EGb
Renal distal tubule18c  Healthy urinary tractc
Renal collecting ducts18c 
Renal calycesc 
Pyelumc 
Ureterc 
Bladder66c 
Urethrac 
EG, ethylene glycol.
aPrimary hyperoxalurias.
bPoisoning/experimental animals treated with EG.
cCrystals are commonly present in these areas. If crystals are damaging in these
areas, all individuals should suffer from crystal-induced urinary tract injury.
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method that was used for the identification of NRP in IMCD
was applied to find crystal-binding molecules at the surface
of MDCK-I cells. Proteins isolated with CaOx affinity
chromatography were trypsin-digested, separated, and
microsequenced. Peptide mixtures were subjected to mass
spectrometry and protein identification confirmed by
Western blotting. These studies revealed Ax-II as the most
prominent apical membrane crystal-binding protein. Pre-
incubating the cells with anti-Ax-II antibodies inhibited
CaOx crystal binding.32 The role of Ax-II in crystal binding
was supported in an experimental cell culture model
for Dent’s disease.33 Dent’s disease is a genetic disorder
associated with low molecular weight proteinuria, hyper-
calciuria, nephrocalcinosis, kidney stones, and renal failure.
This disease is caused by mutations in a renal chloride
channel gene, CLCN5. Crystal binding was studied to IMCD
cells in which clc-5 was disrupted by antisense clc-5 or by
overexpression of truncated clc-5. The disruption of clc-5
resulted in the translocation of Ax-II from the cytoplasm
to the luminal cell surface, which was accompanied
with increased levels of crystal binding that could be blocked
with Ax-II antibodies.33
Osteopontin
Osteopontin (OPN) is a phosphorylated glycoprotein with
crystal-binding properties.34 The role of this protein in the
development of renal calcifications is controversial. High
OPN levels are found in urine, hence urinary OPN is
sometimes called uropontin. In healthy people, the urinary
excretion of uropontin is about 4000 mg/day.35 In another
study, 20 mg/g creatinine was reported.36 In contrast to urine,
normal renal tissue does not contain much OPN and is even
undetectable by Western blotting.37 Consequently, it seems
that OPN is produced in the renal tubules for export to the
urine. In vitro, OPN acts as an inhibitor of crystal nucleation,
growth, aggregation, and retention.38,39 In addition, OPN
favors formation of CaOx dihydrate over CaOx monohydrate
crystals. CaOx dihydrate is less adherent to renal epithelial
cells than CaOx monohydrate.40 In conclusion, there are
many indications suggesting that OPN is an important
inhibitor of nephrolithiasis. A crystal-inducing diet indeed
produced tubular nephrocalcinosis in OPN knockout mice,
but not in wild-type mice.41 Whereas OPN is moderately
expressed in healthy kidneys, its expression is strongly
upregulated in damaged kidneys where OPN also becomes
expressed at the luminal surface of the cells lining the renal
distal tubule. Taking into account the affinity of OPN for
CaOx crystals, this suggests that crystals can be retained by
OPN in the renal tubules of damaged kidneys. A reduced
expression of OPN at the surface of MDCK cells indeed
resulted in lower levels of crystal binding.42 In our cell
culture, animal, and clinical studies, OPN was always
expressed at the luminal surface of crystal binding cells
together with hyaluronan (HA) and CD44 (see below). The
colocalization of crystals and OPN at the cell surface,
however, does not prove that the crystals actually bind to
OPN. Furthermore, in a recent study investigating the
chronology of HA, OPN and CD44 expression on the one
hand and crystal retention on the other did not support a
promoter role for OPN in crystal retention (unpublished
results).
Hyaluronan
HA is a linear glycosaminoglycan composed of multiple units
of glucuronic acid and N-acetylglucosamine (GlcUA-
GlcNAc-)n. During dynamic morphogenetic processes such
as inflammation, wound healing, embryonic development,
and cancer, hydrated coats of HA around cells provide the
microenvironment conducive to tissue remodeling.43 In
MDCK-I cells it was observed that CaOx crystals bind to
non-regenerating/(re)differentiating cells in subconfluent or
healing cultures, but not to intact confluent monolayers.
Evidence for HA involvement in crystal binding is multiple:
(1) in both confocal laser-scanning microscopy and meta-
bolic-labeling studies (using [3H]glucosamine as precursor
for HA biosynthesis), it was observed that HA is expressed
and produced by cells in subconfluent or healing cultures,
but hardly by growth-inhibited cells in confluent cultures,
(2) crystal binding to proliferating MDCK-I cells was
decreased by Streptomyces hyaluronidase, an enzyme that
hydrolyzes HA, but no other GAGs or proteins, (3) crystals
bind to HA immobilized on plastic dishes.44 To confirm these
findings in a human-cell model, these studies were repeated
in primary cultures of human renal tubular cells. Crystal
binding occurred in subconfluent cultures and was absent in
confluent cultures. Confocal laser-scanning microscopy
demonstrated the expression of HA (and OPN) and the
cell surface HA receptor CD44 at the apical membrane
of proliferating tubular cells, whereas at confluence CD44
was expressed at the basolateral membrane and HA (and
OPN) were no longer detectable. In addition, a particle
exclusion technique revealed that proliferating cells were
surrounded by HA-rich pericellular matrices or ‘cell coats’
extending several microns from the cell surface. Disintegra-
tion of these coats with hyaluronidase significantly decreased
the cell surface affinity for crystals.24,45 In the next step our in
vitro observations were tested in a rat model of renal
calcification.46 Rats were fed ethylene glycol, a nephrotoxic
precursor of oxalate, giving rise to tubular epithelial damage
and crystalluria. The results of this study suggested that
crystal retention does not depend on the amount of crystals
formed, but on the presence of a tubular epithelium with
crystal-binding phenotype. This phenotype is characterized
by tubular cell regeneration (which occurs alongside tubular
damage) going along with luminal expression of HA OPN
and CD44.
CLINICAL IMPLICATIONS OF RENAL TUBULAR
NEPHROCALCINOSIS
Our experimental in vitro and in vivo data were recently
supported by clinical observations in preterm and trans-
planted human kidneys. Kidneys of preterm infants are
16 Kidney International (2007) 72, 13–18
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immature and contain tubules with flattened differentiating
(developing) cells that abundantly express HA and OPN at
the luminal cell side.9 In this context, it is worth mentioning
that kidneys of preterm-born infants presents an incidence of
tubular nephrocalsinosis as high as 60%, probably leading to
a prolonged decrease in renal function.47,48 Hence, in this
clinical setting we may reasonably assume that crystal reten-
tion results from exposure of the differentiating epithelium
to periods of crystalluria, possibly caused by furosemide
treatment in combination with a high-protein diet. Trans-
planted kidneys recover from ischemic injury and are chroni-
cally stressed by nephrotoxic immunosuppressive agents
and several other potential nephrotoxins. Intratubular
microcalcifications, not seen in implantation biopsies, are
encountered in up to 40% of the renal allografts after 1 year
and has been associated with poor long-term graft survival.6
Sequential protocol biopsies showed increased intratubular
expression of HA and OPN preceding the retention of
crystals, which were formed under the influence of renal
tubular acidosis-induced hypocitraturia49 and hyperoxaluria
resulting from the release of oxalate from body stores.50 This
demonstrates that the retention-prone epithelial phenotype
precedes crystal adhesion leading to tubular nephrocalcino-
sis. The clinical implications of these findings become even
more important knowing that several disorders are asso-
ciated with tubular nephrocalcinosis, such as patients with
Crohn’s disease,51 interstinal bypass,52 primary hyperoxal-
uria,53 sarcoidosis,54 Dent’s disease,55 carbonic anhydrase
deficiency,56 renal tubular acidosis,57 Bartter’s syndrome,58
cystic fibrosis59 Sjo¨rgen syndrome,60 and acute phosphate
nephropathy.61,62
CONCLUSION
The general picture emerging from these data is that CaOx
crystals preferentially bind to regenerating/(re)diffentiating
renal tubular cells. Several molecules have been proposed as
crystal-binding substance, including NRP, annexin-II, osteo-
pontin, and HA. Although their relative contribution to
crystal binding remains to be determined, these molecules are
exclusively expressed at the luminal surface of regenerating
renal tubular cells. Our next assignment is to find out if this
phenotype is expressed in other disorders that are associated
with nephrocalcinosis, in addition to the kidneys of preterm
infants and renal allograft recipients. We also have to
investigate further the possible relationship between tubular
nephrocalcinosis and nephrolithiasis. Finally, it will be
interesting to find out if the crystal-binding molecules
described in this review not only play a role in tubular
nephrocalcinosis, but also in interstitial nephrocalcinosis and
nephrolithiasis.
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